Search

Your search keyword '"Cabac-Pogorevici, Irina"' showing total 13 results
Start Over Author "Cabac-Pogorevici, Irina"
13 results on '"Cabac-Pogorevici, Irina"'

1. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

Author

Lund, Lars H., Crespo-Leiro, María Generosa, Laroche, Cecile, García-Pinilla, José M., Bennis, Ahmed, Vataman, Eleonora B., Polovina, Marija, Radovanovic, Slavica, Apostolovic, Svetlana R., Asanin, Milika, Gackowski, Andrzej, Kaplon-Cieslicka, Agnieszka, Cabac-Pogorevici, Irina, Anker, Stefan D., Chioncel, Ovidiu, Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, Mcdonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo, Rosano, Giuseppe M., Ruschitzka, Frank, Savarese, Gianluigi, Seferovic, Petar, Lung, Bernard, Popescu, Bogdan A., Maggioni, Aldo P., Lund, Lars H., Crespo-Leiro, María Generosa, Laroche, Cecile, García-Pinilla, José M., Bennis, Ahmed, Vataman, Eleonora B., Polovina, Marija, Radovanovic, Slavica, Apostolovic, Svetlana R., Asanin, Milika, Gackowski, Andrzej, Kaplon-Cieslicka, Agnieszka, Cabac-Pogorevici, Irina, Anker, Stefan D., Chioncel, Ovidiu, Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, Mcdonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo, Rosano, Giuseppe M., Ruschitzka, Frank, Savarese, Gianluigi, Seferovic, Petar, Lung, Bernard, Popescu, Bogdan A., and Maggioni, Aldo P.

Abstract

[Abstract] Aims: Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries. Methods: Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes. Conclusion: The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.

Published
2023

2. Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery

Author

Lund, Lars H; https://orcid.org/0000-0003-1411-4482, Crespo-Leiro, Maria Generosa, Laroche, Cecile, Garcia-Pinilla, Jose M, Bennis, Ahmed, Vataman, Eleonora B, Polovina, Marija, Radovanovic, Slavica, Apostolovic, Svetlana R, Ašanin, Milika, Gackowski, Andrzej, Kaplon-Cieslicka, Agnieszka, Cabac-Pogorevici, Irina, Anker, Stefan D, Chioncel, Ovidiu; https://orcid.org/0000-0002-3197-3628, Coats, Andrew J S; https://orcid.org/0000-0002-2771-4260, Filippatos, Gerasimos; https://orcid.org/0000-0002-5640-0332, Lainscak, Mitja; https://orcid.org/0000-0002-5922-4098, McDonagh, Theresa; https://orcid.org/0000-0003-1305-9602, Mebazaa, Alexandre, Metra, Marco; https://orcid.org/0000-0001-6691-8568, Piepoli, Massimo; https://orcid.org/0000-0003-1124-234X, Rosano, Giuseppe M, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Savarese, Gianluigi; https://orcid.org/0000-0001-7732-0887, Seferović, Petar M, Iung, Bernard; https://orcid.org/0000-0002-9127-348X, Popescu, Bogdan A; https://orcid.org/0000-0001-6122-8533, Maggioni, Aldo P; https://orcid.org/0000-0003-2764-6779, ESC EORP HF III National Leaders and Investigators, Lund, Lars H; https://orcid.org/0000-0003-1411-4482, Crespo-Leiro, Maria Generosa, Laroche, Cecile, Garcia-Pinilla, Jose M, Bennis, Ahmed, Vataman, Eleonora B, Polovina, Marija, Radovanovic, Slavica, Apostolovic, Svetlana R, Ašanin, Milika, Gackowski, Andrzej, Kaplon-Cieslicka, Agnieszka, Cabac-Pogorevici, Irina, Anker, Stefan D, Chioncel, Ovidiu; https://orcid.org/0000-0002-3197-3628, Coats, Andrew J S; https://orcid.org/0000-0002-2771-4260, Filippatos, Gerasimos; https://orcid.org/0000-0002-5640-0332, Lainscak, Mitja; https://orcid.org/0000-0002-5922-4098, McDonagh, Theresa; https://orcid.org/0000-0003-1305-9602, Mebazaa, Alexandre, Metra, Marco; https://orcid.org/0000-0001-6691-8568, Piepoli, Massimo; https://orcid.org/0000-0003-1124-234X, Rosano, Giuseppe M, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Savarese, Gianluigi; https://orcid.org/0000-0001-7732-0887, Seferović, Petar M, Iung, Bernard; https://orcid.org/0000-0002-9127-348X, Popescu, Bogdan A; https://orcid.org/0000-0001-6122-8533, Maggioni, Aldo P; https://orcid.org/0000-0003-2764-6779, and ESC EORP HF III National Leaders and Investigators

Abstract

AIMS Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries. METHODS Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes. CONCLUSION The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.

Published
2023

4. Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry

Author

Sokolski, Mateusz, primary, Trenson, Sander, additional, Sokolska, Justyna M., additional, D'Amario, Domenico, additional, Meyer, Philippe, additional, Poku, Nana K., additional, Biering‐Sørensen, Tor, additional, Højbjerg Lassen, Mats C., additional, Skaarup, Kristoffer G., additional, Barge‐Caballero, Eduardo, additional, Pouleur, Anne‐Catherine, additional, Stolfo, Davide, additional, Sinagra, Gianfranco, additional, Ablasser, Klemens, additional, Muster, Viktoria, additional, Rainer, Peter P., additional, Wallner, Markus, additional, Chiodini, Alessandra, additional, Heiniger, Pascal S., additional, Mikulicic, Fran, additional, Schwaiger, Judith, additional, Winnik, Stephan, additional, Cakmak, Huseyin A., additional, Gaudenzi, Margherita, additional, Mapelli, Massimo, additional, Mattavelli, Irene, additional, Paul, Matthias, additional, Cabac‐Pogorevici, Irina, additional, Bouleti, Claire, additional, Lilliu, Marzia, additional, Minoia, Chiara, additional, Dauw, Jeroen, additional, Costa, Jérôme, additional, Celik, Ahmet, additional, Mewton, Nathan, additional, Montenegro, Carlos E.L., additional, Matsue, Yuya, additional, Loncar, Goran, additional, Marchel, Michal, additional, Bechlioulis, Aris, additional, Michalis, Lampros, additional, Dörr, Marcus, additional, Prihadi, Edgard, additional, Schoenrath, Felix, additional, Messroghli, Daniel R., additional, Mullens, Wilfried, additional, Lund, Lars H., additional, Rosano, Giuseppe M.C., additional, Ponikowski, Piotr, additional, Ruschitzka, Frank, additional, and Flammer, Andreas J., additional

Published
2021
Full Text
View/download PDF

5. Hyponatraemia in heart failure: time for new solutions?

Author

Kapłon-Cieślicka, Agnieszka, Soloveva, Anzhela, Mareev, Yura, Cabac-Pogorevici, Irina, Verbrugge, Frederik Hendrik, and Vardas, Panagiotis

Abstract

Hyponatraemia is very common in heart failure (HF), especially in decompensated patients. It is associated with increased mortality and morbidity and considered a marker of advanced disease. Recognition of hyponatraemia and its causes may help guide treatment strategy. Historically, therapy has primarily focused on water restriction, decongestion with loop diuretics in case of volume overload (dilutional hyponatraemia) and sodium repletion in case of depletion. In this review, we summarise the potential benefits of established and emerging HF therapies on sodium homeostasis, with a focus on dual vasopressin antagonists, angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors and hypertonic saline, and propose a potential therapeutic approach for hyponatraemia in HF. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. INTRARENAL HEMODYNAMICS IN ARTERIAL HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION

Author

Cabac-Pogorevici Irina and Revenco Valeriu

Subjects
heart failure with preserved ejection fraction, arterial hypertension, lcsh:R, lcsh:Surgery, lcsh:Medicine, lcsh:RD1-811, intrarenal hemodynamics
Abstract

Objectives. Traditional cardiovascular risk factors, in the general population, are usually correlated with the prognosis, in patients with heart failure with preserved ejection fraction. The aim of the study was to assess the implications of intrarenal hemodynamics in heart failure with preserved ejection fraction. Material and Methods. The research included 60 patients with heart failure with preserved ejection fraction, aged 18-79 years. All subjects underwent the following physical examination: 24-hours ambulatory blood pressure and electrocardiography monitoring, echocardiography, intrarenal Doppler ultrasound, obtaining the following parameters of the intrarenal hemodynamics: renal resistive index, renal pulsatile index, acceleration time. Results. The analysis of blood pressure values showed that 22% (13 patients) had stage I arterial hypertension, 48% (29 patients) – stage II arterial hypertension and 30% (18 patients) – stage III arterial hypertension, while the mean age of arterial hypertension onset was 40,55 ± 10,27 years, the mean arterial hypertension duration being 9,57 ± 7,12 years, mean ejection fraction – 56 ± 4,562%, mean natriuretic peptide levels – 654 ± 93 pg/ml. There was a positive association of renal resistive index with ambulatory 24 hours systolic blood pressure (r=0,359, p < 0,01), mean daytime systolic blood pressure (r=0,260, p Conclusions. In addition to local renal vascular properties, the central hemodynamic factors significantly influence the intrarenal hemodynamics in heart failure with preserved ejection fraction. intrarenal hemodynamics is the result of a complex interaction between renal and systemic vascular factors useful in assessment of a large spectrum of cardiovascular conditions.

Published
2020

7. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry.

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Département cardiovasculaire, Sokolski, Mateusz, Trenson, Sander, Sokolska, Justyna M, D'Amario, Domenico, Meyer, Philippe, Poku, Nana K, Biering-Sørensen, Tor, Højbjerg Lassen, Mats C, Skaarup, Kristoffer G, Barge-Caballero, Eduardo, Pouleur, Anne-Catherine, Stolfo, Davide, Sinagra, Gianfranco, Ablasser, Klemens, Muster, Viktoria, Rainer, Peter P, Wallner, Markus, Chiodini, Alessandra, Heiniger, Pascal S, Mikulicic, Fran, Schwaiger, Judith, Winnik, Stephan, Cakmak, Huseyin A, Gaudenzi, Margherita, Mapelli, Massimo, Mattavelli, Irene, Paul, Matthias, Cabac-Pogorevici, Irina, Bouleti, Claire, Lilliu, Marzia, Minoia, Chiara, Dauw, Jeroen, Costa, Jérôme, Celik, Ahmet, Mewton, Nathan, Montenegro, Carlos E L, Matsue, Yuya, Loncar, Goran, Marchel, Michal, Bechlioulis, Aris, Michalis, Lampros, Dörr, Marcus, Prihadi, Edgard, Schoenrath, Felix, Messroghli, Daniel R, Mullens, Wilfried, Lund, Lars H, Rosano, Giuseppe M C, Ponikowski, Piotr, Ruschitzka, Frank, Flammer, Andreas J, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Département cardiovasculaire, Sokolski, Mateusz, Trenson, Sander, Sokolska, Justyna M, D'Amario, Domenico, Meyer, Philippe, Poku, Nana K, Biering-Sørensen, Tor, Højbjerg Lassen, Mats C, Skaarup, Kristoffer G, Barge-Caballero, Eduardo, Pouleur, Anne-Catherine, Stolfo, Davide, Sinagra, Gianfranco, Ablasser, Klemens, Muster, Viktoria, Rainer, Peter P, Wallner, Markus, Chiodini, Alessandra, Heiniger, Pascal S, Mikulicic, Fran, Schwaiger, Judith, Winnik, Stephan, Cakmak, Huseyin A, Gaudenzi, Margherita, Mapelli, Massimo, Mattavelli, Irene, Paul, Matthias, Cabac-Pogorevici, Irina, Bouleti, Claire, Lilliu, Marzia, Minoia, Chiara, Dauw, Jeroen, Costa, Jérôme, Celik, Ahmet, Mewton, Nathan, Montenegro, Carlos E L, Matsue, Yuya, Loncar, Goran, Marchel, Michal, Bechlioulis, Aris, Michalis, Lampros, Dörr, Marcus, Prihadi, Edgard, Schoenrath, Felix, Messroghli, Daniel R, Mullens, Wilfried, Lund, Lars H, Rosano, Giuseppe M C, Ponikowski, Piotr, Ruschitzka, Frank, and Flammer, Andreas J

Abstract

We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001). Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.

Published
2021

9. Renal and carotid resistive indexes and left ventricular remodelling in arterial hypertension

Author

Cabac-Pogorevici, Irina

Subjects
Cardiovascular system, genetic structures, Arteries / Aorta, Echocardiography, Arterial access, Calcifications / Calculi, Ultrasound, Hypertension, Audit and standards, Haemodynamics / Flow dynamics, Ultrasound-Power Doppler, Cardiac, Ablation procedures
Abstract

Aims and objectives Methods and materials Results Conclusion Personal information References, Aims and objectives: The resistive index is a hemodynamic parameter determined by Doppler sonography that reflects vascular resistance of the arterial vascular bed. Intrarenal haemodynamic alterations, assessed by ultrasonographic intraparenchymal renal resistive index...

Published
2019
Full Text
View/download PDF

10. Heart failure and central sleep apnea in the era of implantable recorders.

Author

Cabac-Pogorevici, Irina and Revenco, Valeriu

Subjects
*SLEEP apnea syndromes, *HEART failure, *ARRHYTHMIA, *VENTRICULAR ejection fraction, *BRAIN natriuretic factor
Abstract

Sleep-disordered breathing (SDB) is a complex syndrome with a high prevalence and a significant impact on the general well-being of the overall population. Heart failure (HF) is a major health issue with an increasing incidence, a high rate of hospitalizations, and high mortality in developing countries. Focusing on early recognition and management of HF comorbidities may have an important role in reducing the economic burden and public health impact of HF. The close interconnection between HF, heart rhythm disturbances, and sleep apnea is supported by the mutual risk factors such as age, smoking, obesity, and male sex. Central sleep apnea (CSA) may be considered a marker of advanced HF, often being associated with elevated pulmonary capillary wedge pressure, brain natriuretic peptide (BNP), and noradrenaline levels and with low left ventricular ejection fraction. In the same way, there is an important correlation between CSA and different types of arrhythmias. The large intraindividual rhythm variability reported in patients with SDB who underwent continuous monitoring by implantable loop recorder (ILR) demonstrated the incapacity of 24-hour and 48-hour Holter monitoring to accurately determine the incidence of cardiac arrhythmias. In patients with HF and CSA, the extended cardiac monitoring by ILR becomes compulsory because in-time interventions could be life saving, but with the absolute lack of solid evidence in this field, there is an acute need for extensive randomized trials to further highlight the potential beneficial effect of ILR monitoring in patients with CSA and HF. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Intrarenal hemodynamics and left ventricular geometry in patients with arterial hypertension

Author

Cabac-Pogorevici, Irina

Subjects
genetic structures, Echocardiography, Arteriosclerosis, Vascular, Hypertension, Haemodynamics / Flow dynamics, Ultrasound-Spectral Doppler, Ultrasound-Colour Doppler, Kidney, Imaging sequences, Diagnostic procedure
Abstract

Aims and objectives Methods and materials Results Conclusion Personal information References, Aims and objectives: In the last decades a particular attention was paid to the identification of early markers of asymptomatic target organ damage, such as left ventricular hypertrophy in arterial hypertension, because they allow early evaluation of global...

Published
2017
Full Text
View/download PDF

12. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

Author

Nathan Mewton, Tor Biering-Sørensen, Marcus Dörr, Andreas J. Flammer, Michał Marchel, Wilfried Mullens, Domenico D'Amario, Yuya Matsue, Huseyin A. Cakmak, Gianfranco Sinagra, Davide Stolfo, Kristoffer Grundtvig Skaarup, Claire Bouleti, Marzia Lilliu, Felix Schoenrath, Edgard Prihadi, Irene Mattavelli, Justyna M. Sokolska, Carlos Eduardo Lucena Montenegro, Daniel Messroghli, Anne-Catherine Pouleur, Frank Ruschitzka, Matthias Paul, Nana K. Poku, Lampros K. Michalis, Mateusz Sokolski, Jérôme Costa, Alessandra Chiodini, Viktoria Muster, Jeroen Dauw, Goran Loncar, Peter P. Rainer, Philippe Meyer, Eduardo Barge-Caballero, Massimo Mapelli, Aris Bechlioulis, Fran Mikulicic, Ahmet Çelik, Piotr Ponikowski, Klemens Ablasser, Chiara Minoia, Judith Schwaiger, Sander Trenson, Markus Wallner, Lars Lund, Giuseppe M.C. Rosano, P S Heiniger, Mats Christian Højbjerg Lassen, Margherita Gaudenzi, Irina Cabac-Pogorevici, Stephan Winnik, University of Wrocław [Poland] (UWr), University hospital of Zurich [Zurich], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Geneva University Hospital (HUG), Herlev and Gentofte Hospital, University of Copenhagen = Københavns Universitet (UCPH), Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] (CHUAC), Instituto de Investigación Biomédica de A Coruña [La Corogne, Espagne] (INIBIC), A Coruña University Hospital [La Corogne, Espagne], Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), Cliniques universitaires St Luc [Bruxelles], Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain = Catholic University of Louvain (UCL), Università degli studi di Trieste = University of Trieste, Medical University of Graz, Temple University [Philadelphia], Pennsylvania Commonwealth System of Higher Education (PCSHE), Center for Biomarker Research in Medicine [Graz, Austria] (CBmed GmbH), Mustafakemalpasa State Hospital [Bursa, Turkey] (MSH), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Università degli Studi di Milano = University of Milan (UNIMI), Johns Hopkins University Applied Physics Laboratory [Laurel, MD] (APL), Luzerner Kantonsspital [Lucerne, Switzerland] (LUKS), University Nicolae Testemitanu [Kishinev, Moldova] (UNT), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital 'Magalini' Villafranca - ULSS 9 Scaligera [Verona, Italy], Public Health Company Valle Olona [Busto Arsizio, Italy] (PHCVO), Ziekenhuis Oost-Limburg (ZOL), Hasselt University (UHasselt), Centre Hospitalier Universitaire de Reims (CHU Reims), Mersin University, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Universidade Federal de Pernambuco [Recife] (UFPE), Juntendo University Hospital [Tokyo], Institute for Cardiovascular Diseases Dedinje [Belgrade, Serbia] (IC2D), University of Belgrade [Belgrade], Medical University of Warsaw - Poland, University Hospital of Ioannina, University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), ZNA Heart Centre [Antwerp, Belgium], German Heart Institute Berlin [Berlin, Germany] (GHIB), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Deutsches Herzzentrum Berlin, Karolinska Institute, Karolinska University Hospital [Stockholm], IRCCS San Raffaele [Rome, Italy], Wrocław Medical University, CarMeN, laboratoire, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de cardiologie, Mapelli, Massimo/0000-0001-9985-7407, celik, Ahmet/0000-0002-9417-7610, Sokolski, Mateusz/0000-0001-9925-3566, Sokolska, Justyna/0000-0002-4759-5879, Lassen, Mats/0000-0002-2255-582X, Skaarup, Kristoffer/0000-0002-2690-7511, Sokolski, Mateusz, Trenson, Sander, Sokolska, Justyna M., D'Amario, Domenico, Meyer, Philippe, Poku, Nana K., Biering-Sorensen, Tor, Lassen, Mats C. Hojbjerg, Skaarup, Kristoffer G., Barge-Caballero, Eduardo, Pouleur, Anne-Catherine, Stolfo, Davide, Sinagra, Gianfranco, Ablasser, Klemens, Muster, Viktoria, Rainer, Peter P., Wallner, Markus, Chiodini, Alessandra, Heiniger, Pascal S., Mikulicic, Fran, Schwaiger, Judith, Winnik, Stephan, Cakmak, Huseyin A., Gaudenzi, Margherita, Mapelli, Massimo, Mattavelli, Irene, Paul, Matthias, Cabac-Pogorevici, Irina, Bouleti, Claire, Lilliu, Marzia, Minoia, Chiara, DAUW, Jeroen, Costa, Jerome, Celik, Ahmet, Mewton, Nathan, Montenegro, Carlos E. L., Matsue, Yuya, Loncar, Goran, Marchel, Michal, Bechlioulis, Aris, Michalis, Lampros, Dorr, Marcus, Prihadi, Edgard, Schoenrath, Felix, Messroghli, Daniel R., MULLENS, Wilfried, Lund, Lars H., Rosano, Giuseppe M. C., Ponikowski, Piotr, Ruschitzka, Frank, and Flammer, Andreas J.

Subjects
Male, Cardiac & Cardiovascular Systems, [SDV]Life Sciences [q-bio], Disease, 030204 cardiovascular system & hematology, 0302 clinical medicine, Interquartile range, Original Research Articles, Clinical endpoint, Original Research Article, Hospital Mortality, Registries, 030212 general & internal medicine, Incidence (epidemiology), Cardiovascular disease, 3. Good health, [SDV] Life Sciences [q-bio], Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, SARS‐CoV2, Heart failure, CORONAVIRUS DISEASE 2019, SARS-CoV2, 03 medical and health sciences, COVID‐19, Diabetes mellitus, Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, Humans, Aged, Retrospective Studies, Heart Failure, Science & Technology, SARS-CoV-2, business.industry, COVID-19, Odds ratio, medicine.disease, Confidence interval, Risk factors, RC666-701, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Cardiovascular System & Cardiology, INHIBITORS, business
Abstract

AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P

Published
2021
Full Text
View/download PDF

13. Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery.

Author

Lund LH, Crespo-Leiro MG, Laroche C, Garcia-Pinilla JM, Bennis A, Vataman EB, Polovina M, Radovanovic S, Apostolovic SR, Ašanin M, Gackowski A, Kaplon-Cieslicka A, Cabac-Pogorevici I, Anker SD, Chioncel O, Coats AJS, Filippatos G, Lainscak M, Mcdonagh T, Mebazaa A, Metra M, Piepoli M, Rosano GM, Ruschitzka F, Savarese G, Seferović PM, Iung B, Popescu BA, and Maggioni AP

Subjects
Humans, Quality of Life, Europe epidemiology, Ambulatory Care, Registries, Heart Failure therapy, Heart Failure drug therapy
Abstract

Aims: Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries., Methods: Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes., Conclusion: The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results